Poly(γ-glutamic acid) nanoparticles as an efficient antigen delivery and adjuvant system: Potential for an AIDS vaccine

Journal of Medical Virology

Volumn 80, Issue 1, 2008, Pages 11-19

  Wang, Xin ^a,b   Uto, Tomofumi ^a,b   Akagi, Takami ^b,c   Akashi, Mitsuru ^b,c   Baba, Masanori ^a,b  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^c OSAKA UNIVERSITY   (Japan)

Author keywords

Adjuvant; Antigen delivery; Dendritic cell; HIV 1; Nanoparticle

Indexed keywords

ANTIGEN P24; FREUND ADJUVANT; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NANOPARTICLE; OVALBUMIN; POLY(GAMMA GLUTAMIC ACID); UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN DELIVERY SYSTEM; ANTIGEN SPECIFICITY; ARTICLE; BAGG ALBINO MOUSE; CELL ENCAPSULATION; CELL MATURATION; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; DRUG DELIVERY SYSTEM; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNIZATION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; SPLEEN CELL; T LYMPHOCYTE;

ADJUVANTS, IMMUNOLOGIC; ADJUVANTS, PHARMACEUTIC; AIDS VACCINES; ANIMALS; ANTIBODY FORMATION; ANTIGENS, VIRAL; DENDRITIC CELLS; DRUG DELIVERY SYSTEMS; HIV-1; HUMANS; INTERFERON TYPE II; MICE; NANOPARTICLES; OVALBUMIN; POLYGLUTAMIC ACID; T-LYMPHOCYTES;

HUMAN IMMUNODEFICIENCY VIRUS 1; MUS;

EID: 36849058878     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21029     Document Type: Article

References (33)

1. Akagi T, Kawamura M, Ueno M, Hiraishi K, Adachi M, Serizawa T, Akashi M, Baba M. 2003. Mucosal immunization with inactivated HIV-1-capturing nanospheres induces a significant HIV-1-specific vaginal antibody response in mice. J Med Virol 69:163-172.
2. Akagi T, Higashi M, Kaneko T, Kida T, Akashi M. 2005a. In vitro enzymatic degradation of nanoparticles prepared from hydropho-bically-modified poly(γ-glutamic acid). Macromol Biosci 5:598-602.
3. Akagi T, Kaneko T, Kida T, Akashi M. 2005b. Preparation and characterization of biodegradable nanoparticles based on poly(γ-glutamic acid) with l-phenylalanine as a protein carrier. J Control Release 108:226-236.
4. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, Pulendran B, Palucka K. 2000. Immunobiology of dendritic cells. Annu Rev Immunol 18:767-811.
5. Elamanchili P, Diwan M, Cao M, Samuel J. 2004. Characterization of poly(D,L-lactic-co-glycolic acid) based nanoparticulate system for enhanced delivery of antigens to dendritic cells. Vaccine 22:2406-2412.
6. Fonteneau JF, Kavanagh DG, Lirvall M, Sanders C, Cover TL, Bhardwaj N, Larsson M. 2003. Characterization of the MHC class I cross-presentation pathway for cell-associated antigens by human dendritic cells. Blood 102:4448-4455.
7. Guermonprez P, Saveanu L, Kleijmeer M, Davoust J, Van Endert P, Amigorena S. 2003. ER-phagosome fusion defines an MHC class I cross-presentation compartment in dendritic cells. Nature 425:397-402.
8. Jilek S, Merkle HP, Walter E. 2005. DNA-loaded biodegradable microparticles as vaccine delivery systems and their interaction with dendritic cells. Adv Drug Deliv Rev 57:377-390.
9. Kawamura M, Naito T, Ueno M, Akagi T, Hiraishi K, Takai I, Makino M, Serizawa T, Sugimura K, Akashi M, Baba M. 2002. Induction of mucosal IgA following intravaginal administration of inactivated HIV-1-capturing nanospheres in mice. J Med Virol 66:291-298.
10. Kawamura M, Wang X, Uto T, Sato K, Ueno M, Akagi T, Hiraishi K, Matsuyama T, Akashi M, Baba M. 2005. Induction of dendritic cell-mediated immune responses against HIV-1 by antigen-capturing nanospheres in mice. J Med Virol 76:7-15.
11. Kerkmann M, Lochmann D, Weyermann J, Marschner A, Poeck H, Wagner M, Battiany J, Zimmer A, Endres S, Hartmann G. 2006. Immunostimulatory properties of CpG-oligonucleotides are enhanced by the use of protamine nanoparticles. Oligonucleotides 16:313-322.
12. Labeur MS, Roters B, Pers B, Mehling A, Luger TA, Schwarz T, Grabbe S. 1999. Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage. J Immunol 162:168-175.
13. Levine MM, Sztein MB. 2004. Vaccine development strategies for improving immunization: The role of modern immunology. Nat Immunol 5:460-464.
14. Lutsiak ME, Robinson DR, Coester C, Kwon GS, Samuel J. 2002. Analysis of poly(D,L-lactic-co-glycolic acid) nanosphere uptake by human dendritic cells and macrophages in vitro. Pharm Res 19:1480-1487.
15. Maloy KJ, Donachie AM, O'Hagan DT, Mowat AM. 1994. Induction of mucosal and systemic immune responses by immunization with ovalbumin entrapped in poly(lactide-co-glycolide) microparticles. Immunology 81:661-667.
16. Mascola JR, Lewis MG, Stiegler G, Harris D, VanCott TC, Hayes D, Louder MK, Brown CR, Sapan CV, Frankel SS, Lu Y, Robb ML, Katinger H, Birx DL. 1999. Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol 73:4009-4018.
17. Matsusaki M, Hiwatari K, Higashi M, Kaneko T, Akashi M. 2004. Stably-dispersed and surface-functional bionanoparticles prepared by self-assembling amphipathic polymers of hydrophilic poly(γ-glutamic acid) bearing hydrophobic amino acids. Chem Lett 33:398-399.
18. Miyake A, Akagi T, Enose Y, Ueno M, Kawamura M, Horiuchi R, Hiraishi K, Adachi M, Serizawa T, Narayan O, Akashi M, Baba M, Hayami M. 2004. Induction of HIV-specific antibody response and protection against vaginal SHIV transmission by intranasal immunization with inactivated SHIV-capturing nanospheres in macaques. J Med Virol 73:368-377.
19. + Th1 cells. Vaccine 13:1741-1749.
20. O'Hagan DT. 1996. The intestinal uptake of particles and the implications for drug and antigen delivery. J Anat 189:477-482.
21. Panyam J, Labhasetwar V. 2003. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev 55:329-347.
22. Petrovsky N, Aguilar JC. 2004. Vaccine adjuvants: Current state and future trends. Immunol Cell Biol 82:488-496.
23. Sato K, Yamashita N, Baba M, Matsuyama T. 2003a. Modified myeloid dendritic cells act as regulatory dendritic cells to induce anergic and regulatory T cells. Blood 101:3581-3589.
24. Sato K, Yamashita N, Baba M, Matsuyama T. 2003b. Regulatory dendritic cells protect mice from murine acute graft-versus-host disease and leukemia relapse. Immunity 18:367-379.
25. + lymphocytes. Science 283:857-860.
26. Singh M, Hioe C, Qiu H, Li XM, Wang CY, Koff W, Zamb T, Nixon DF. 1997. CTL induction using synthetic peptides delivered in emulsions-critical role of the formulation procedure. Vaccine 15:1773-1778.
27. Tamber H, Johansen P, Merkle HP, Gander B. 2005. Formulation aspects of biodegradable polymeric microspheres for antigen delivery. Adv Drug Deliv Rev 57:357-376.
28. Uto T, Wang X, Sato K, Haraguchi M, Akagi T, Akashi M, Baba M. 2007. Targeting of antigen to dendritic cells with poly(γ-glutamic acid) nanoparticles induce antigen-specific humoral and cellular immunity. J Immunol 178:2979-2986.
29. van de Weert M, Hennink WE, Jiskoot W. 2000. Protein instability in poly(lactic-co-glycolic acid) microparticles. Pharm Res 17:1159-1167.
30. Waeckerle-Men Y, Allmen EU, Gander B, Scandella E, Schlosser E, Schmidtke G, Merkle HP, Groettrup M. 2006. Encapsulation of proteins and peptides into biodegradable poly(D,L-lactide-co-glycolide) microspheres prolongs and enhances antigen presentation by human dendritic cells. Vaccine 24:1847-1857.
31. Wang X, Uto T, Sato K, Ide K, Akagi T, Okamoto M, Kaneko T, Akashi M, Baba M. 2005. Potent activation of antigen-specific T cells by antigen-loaded nanospheres. Immunol Lett 98:123-130.
32. Wang X, Akagi T, Akashi M, Baba M. 2007. Development of core-corona type polymeric nanoparticles as an anti-HIV-1 vaccine. Mini-Rev Org Chem 4:51-59.
33. Woodard LF, Jasman RL. 1985. Stable oil-in-water emulsions: Preparation and use as vaccine vehicles for lipophilic adjuvants. Vaccine 3:137-144.